CDA | Evidence Driven
CDA | Evidence Driven

Istodax for Peripheral T-Cell Lymphoma - Details

Details

Files
Generic Name:
Romidepsin
Project Status:
Complete
Therapeutic Area:
Peripheral T-Cell Lymphoma
Manufacturer:
Celgene Inc.
Brand Name:
Istodax
Project Line:
Reimbursement Review
Project Number:
PC0048-000
Performance Metric:
N/A — Predated performance metrics
Strength:
10 mg per vial
Tumour Type:
Lymphoma
Indications:
Peripheral T-Cell Lymphoma
Funding Request:
For patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) who are not eligible for transplant and have received at least one prior systemic therapy
Sponsor:
Celgene Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Files

Provincial Funding Summary View PDF
Romidepsin (Istodax) PTCL – Final Recommendation Final Recommendation May 19, 2015 View PDF
Romidepsin (Istodax) PTCL – Final Clinical Guidance Report Guidance Reports May 19, 2015 View PDF
Romidepsin (Istodax) PTCL – Final Economic Guidance Report Guidance Reports May 19, 2015 View PDF
Romidepsin (Istodax) PTCL - Initial pERC Recommendation Initial Recommendation April 30, 2015 View PDF
Romidepsin (Istodax) PTCL – PAG Feedback on Initial Recommendation Feedback May 19, 2015 View PDF
Romidepsin (Istodax) PTCL – Manufacturer Feedback on Initial Recommendation Feedback May 19, 2015 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : June 26, 2015